ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Allogene Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.30−0.01 (-0.76%)
Close on Oct 19, 2026
- Market cap
- $427.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Allogene Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -53.4%
Financial strength
- Current ratio
- 10.72
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 121.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.98
- Dividend yield
- 0.00%